1. Introduction

The legal threshold between therapy and enhancement is the boundary between using medical or biological interventions to prevent, diagnose, or treat disease and using them to improve human capacities beyond a recognised therapeutic objective.

This distinction has become increasingly important in biotechnology, genetic engineering, neurotechnology, reproductive medicine, pharmacology, and human performance modification.

Therapy generally aims to restore, maintain, or protect health and functioning, such as treating a genetic disorder or restoring movement after paralysis.

Enhancement generally aims to increase a person's physical, cognitive, sensory, emotional, or biological capacities beyond a therapeutic baseline, such as improving memory in a healthy person or engineering increased muscle strength.

The distinction is not always clear. A treatment may both cure a disease and improve performance. A person with a disability may seek a capacity that others regard as an enhancement, while an intervention described as treatment may also be intended to influence appearance, social status, or competitive advantage.

Central legal question: When does a medical intervention cease to be a legitimate therapeutic measure and become an enhancement subject to different regulatory, ethical, or constitutional scrutiny?

There is no single universal legal test. The answer depends on the jurisdiction, the intervention's purpose, its evidence of safety and efficacy, the person's consent, the applicable regulatory classification, and the rights potentially affected.

2. Essential legal concepts

Best Medical Clinic in Indore | Kokilaben Hospital in Indore

A. Therapeutic intervention

An intervention directed toward preventing disease, relieving symptoms, correcting dysfunction, or restoring or maintaining health. Examples include gene therapy for a serious inherited disease and medication for a diagnosed medical condition.

About Us | MyosTech

B. Human enhancement

An intervention intended primarily to increase an existing capability beyond an ordinary therapeutic objective. Examples include cognitive-enhancing drugs used by healthy people, elective sensory augmentation, and genetic interventions intended to increase athletic performance.

ZagrebMed - Decoding Your DNA: The Rise of Personalized Medicine

C. Dual-purpose intervention

A procedure that may qualify as therapy and enhancement simultaneously. For example, a treatment that corrects a neuromuscular disorder may also give the patient physical capabilities exceeding those previously available to them.

A crucial distinction is that therapeutic status does not automatically establish legality, and enhancement is not automatically unlawful. Both can be regulated, restricted, or prohibited depending on the circumstances.

3. Legal tests for determining the threshold

Courts and regulators can assess the therapy–enhancement boundary through several related tests. No single test is universally decisive.

A. Purpose-of-intervention test

The first question is why the intervention is being performed.

Treating a diagnosed disease generally supports therapeutic classification.

Preventing a substantial, identifiable medical risk may also be therapeutic.

Improving performance in a healthy person, without a recognised medical indication, generally points toward enhancement.

However, purpose alone is insufficient. A clinician cannot make an unproven procedure lawful merely by calling it therapy.

B. Medical-baseline test

The decision-maker considers the person's condition, functional limitations, medical history, and the intended outcome.

The baseline should not automatically be defined as an average or statistically normal human body. Disability, neurodiversity, age, and individual variation must be considered carefully.

For example, a cochlear implant may restore access to sound for a person with hearing loss, while an experimental device that provides additional sensory channels to a person without hearing impairment may be classified as enhancement. The distinction still depends on the device's actual function, regulatory status, and the person's circumstances.

C. Evidence-of-efficacy test

A procedure presented as treatment should have adequate scientific support for the claimed indication and should comply with applicable approval requirements.

Relevant questions include:

Has the intervention been adequately studied?

Is it approved or otherwise lawfully authorised for the intended use?

Are its benefits proportionate to its risks?

Is the practitioner following accepted professional standards?

Is the intervention being marketed with misleading claims?

This test is especially important in gene editing, stem-cell interventions, unapproved neurotechnology, and experimental regenerative medicine.

D. Proportionality and risk test

The acceptable risk may depend on the seriousness of the condition, the expected benefit, available alternatives, and the intervention's reversibility.

A substantial risk might be justifiable for a serious, otherwise untreatable disease but unacceptable for a marginal increase in memory, height, strength, or cosmetic appearance.

This is not an absolute rule: even life-saving treatment remains subject to safeguards, and some enhancement procedures may be lawful when properly regulated.

E. Consent and autonomy test

The individual must receive accurate information about the intervention's purpose, uncertainties, alternatives, and foreseeable risks.

Consent does not eliminate regulatory requirements, justify professional negligence, or authorise a practitioner to undertake a procedure outside the scope of the patient's consent.

For minors and people unable to provide legally valid consent, additional safeguards may be necessary.

4. Detailed case laws

The following cases are important because they establish principles concerning bodily autonomy, medical consent, professional standards, constitutional liberty, and public-health regulation. Most do not expressly establish a universal legal definition of enhancement; their relevance lies in the legal principles they provide for evaluating the boundary.

Case 1. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1 — India

Directly relevant to consent

Facts: A patient consented to a diagnostic medical procedure. During the procedure, the doctor performed additional surgery without obtaining the patient's specific consent, although the additional intervention was considered beneficial.

Legal issue: Can consent to one medical procedure be treated as consent to a different or more extensive procedure simply because the latter may benefit the patient?

Judgment: The Supreme Court of India held that valid consent must be real and informed. A doctor generally cannot perform an additional, materially different procedure without consent, except in the recognised emergency circumstances described by the Court.

Legal principle: The patient's autonomy and the scope of consent are central to lawful medical intervention.

Application to therapy and enhancement: A patient who consents to disease treatment has not necessarily consented to additional genetic modification, cognitive enhancement, or elective physical alteration. Each materially distinct intervention must be assessed within the scope of the consent given and the applicable law.

Source: Read the judgment and case summary.

(2008) 2 SCC 1

Case 2. K.S. Puttaswamy v. Union of India, (2017) 10 SCC 1 — India

Facts: A nine-judge bench of the Supreme Court considered whether privacy is a fundamental right under the Indian Constitution.

Legal issue: Does constitutional liberty protect personal autonomy, dignity, and decisions concerning one's body and private life?

Judgment: The Court unanimously recognised privacy as a fundamental right under Article 21 and other freedoms guaranteed by Part III of the Constitution.

Legal principle: Personal autonomy, bodily integrity, dignity, and decisional privacy are constitutionally significant, subject to constitutionally valid limitations.

Application to enhancement: The judgment provides a constitutional framework for examining elective genetic interventions, neurotechnology, reproductive choices, and enhancement-related personal decisions. It does not, however, establish an unrestricted fundamental right to demand any biological modification from a doctor or the State.

The legal distinction is between the freedom to make personal decisions and an enforceable entitlement to receive a particular medical procedure.

Case 3. Jacobson v. Massachusetts, 197 U.S. 11 (1905) — United States

Facts: A Massachusetts resident challenged a compulsory smallpox vaccination requirement imposed under public-health legislation.

Legal issue: Does personal liberty prevent the government from imposing vaccination requirements to protect public health?

Judgment: The United States Supreme Court upheld the state's vaccination authority in the circumstances presented, recognising that individual liberty is not absolute when legitimate public-health interests are at stake.

Legal principle: Bodily autonomy may be subject to properly justified public-health regulation.

Application to enhancement: The case illustrates why individual choice cannot be the only legal test for biological interventions. Governments may regulate interventions that create risks for other people or public health. However, Jacobson did not concern genetic enhancement and does not establish that governments may freely compel enhancement or disregard modern constitutional safeguards.

Case 4. Cruzan v. Director, Missouri Department of Health, 497 U.S. 261 (1990) — United States

Facts: Nancy Cruzan was in a persistent vegetative state. Her family sought withdrawal of artificial nutrition and hydration, and the dispute concerned the evidence required to establish her wishes.

Legal issue: Does the Constitution protect a person's interest in refusing unwanted medical treatment?

Judgment: The Court assumed that a competent person's liberty interest includes refusing unwanted medical treatment. It upheld Missouri's evidentiary requirement for determining an incapacitated patient's wishes.

Legal principle: Medical intervention engages questions of personal liberty, bodily integrity, and the evidence required to establish consent or refusal.

Application to enhancement: The case supports the importance of patient choice in medical decision-making, but it does not establish a right to obtain enhancement. Refusing an unwanted intervention and demanding access to a new, potentially risky intervention are legally distinct questions.

Case 5. Yash Charitable Trust v. Union of India, 2026 INSC 96 — India

Highly relevant Indian precedent

Facts: The litigation concerned clinics offering stem-cell interventions for Autism Spectrum Disorder (ASD), with disputed claims about therapeutic benefit, scientific evidence, patient protection, and regulatory oversight.

Legal issue: Could such interventions lawfully be offered as routine clinical treatment despite insufficient evidence of safety and efficacy?

Judgment of 30 January 2026: The Supreme Court held that stem-cell therapy for ASD could not be offered as a routine clinical service outside an approved and monitored research or clinical-trial setting under the prevailing scientific and regulatory framework. It emphasised professional standards of care, adequate information, and protection against therapeutic misconception.

Indian Kanoon

Further development: In its order of 13 October 2026, the Court reiterated that the intervention was not recognised as sound and relevant medical practice on the evidence and regulatory standards then prevailing. It clarified that the position was not an immutable ban on future scientific developments. The order also addressed safeguards for existing patients and prohibited admitting new patients to the intervention outside an approved, monitored research or clinical-trial setting.

Indian Kanoon

Legal principle: Calling an intervention “therapy” does not make it an established treatment. Scientific evidence, applicable regulation, professional duties, and valid consent must all be considered.

Application to enhancement: This is particularly important for genetic modification, regenerative medicine, cognitive enhancement, and other emerging technologies. An intervention may be marketed as therapeutic but still fail the legal standard for routine clinical practice. Conversely, a scientifically validated intervention does not become unlawful merely because it improves functioning beyond a person's previous baseline.

The precise regulatory outcome remains intervention-specific; this judgment does not establish a blanket prohibition on all stem-cell treatments or all human enhancements.

Case 6. Washington v. Glucksberg, 521 U.S. 702 (1997) — United States

Facts: Physicians challenged Washington State's prohibition on physician-assisted suicide, arguing that the Fourteenth Amendment protected the relevant liberty interest.

Legal issue: Does constitutional liberty create an unrestricted right to obtain a particular medical intervention?

Judgment: The Supreme Court rejected the claimed constitutional right to physician-assisted suicide, emphasising historical legal traditions and legitimate state interests, including protection of vulnerable people and the integrity of the medical profession.

Justia U.S. Supreme Court Center+1

Application to enhancement: Although the case is not about enhancement, it illustrates that personal autonomy does not automatically establish a constitutional entitlement to every requested medical procedure. A person may have substantial freedom to make personal choices without having an enforceable right to compel a physician to provide a particular intervention.

Case 7. Buck v. Bell, 274 U.S. 200 (1927) — United States

Facts: The Supreme Court considered a Virginia statute authorising compulsory sterilisation of certain institutionalised people classified as unfit to reproduce.

Judgment: The Court upheld the sterilisation law. The decision is now widely regarded as a notorious example of eugenic abuse and the failure to protect bodily autonomy and equality.

Application to enhancement: This case is best understood as a warning, not as a model for modern enhancement regulation. It demonstrates the dangers of allowing the State to define biological normality, reproductive fitness, or desirable human traits in ways that facilitate coercion and discrimination.

Modern laws governing genetic technologies should therefore include protections against forced interventions, discriminatory selection, and the use of medical authority to impose contested social ideals.

5. Comparative legal framework

The distinction is functional rather than absolute. Some interventions serve both objectives, and the applicable law may regulate the technology itself regardless of whether it is used therapeutically or for enhancement.

6. Application to emerging biotechnology

A. Genetic editing

Correcting a disease-causing mutation in a patient's somatic cells is generally therapeutic. Editing genes to increase height, muscle strength, or cognitive performance in an otherwise healthy person is more likely to be classified as enhancement.

Germline editing raises additional issues because changes may be inherited by future generations. The intervention's purpose alone does not settle its legality; specific restrictions on human embryo research, clinical use, and heritable modification may apply.

B. Cognitive enhancement and neurotechnology

Treating a diagnosed neurological disorder differs from administering a drug or implant to improve memory, concentration, or attention in a healthy individual.

Relevant legal issues include prescription requirements, device authorisation, mental privacy, informed consent, data protection, and the risks of coercion in education or employment.

C. Physical enhancement

Reconstructive surgery following injury is ordinarily therapeutic or rehabilitative. Elective surgery or biological modification to increase strength, endurance, or appearance may be enhancement-oriented.

Even where enhancement is permitted, professional licensing, consumer protection, product safety, and medical-negligence law continue to apply.

D. Reproductive and embryo interventions

Preventing a serious inherited disorder raises different considerations from selecting or modifying traits for preference or competitive advantage.

The analysis may involve reproductive autonomy, embryo-research restrictions, the welfare of future children, equality, and international or national bioethics standards.

7. Indian legal position

In India, the therapy–enhancement distinction must be assessed through the applicable statutory framework and constitutional principles rather than through a single, comprehensive enhancement law.

Key sources include:

Article 21 of the Constitution: Protects life and personal liberty and informs the law concerning dignity, bodily integrity, and autonomy.

Article 14: Requires state action to comply with constitutional equality and non-arbitrariness principles.

Drugs and Cosmetics Act, 1940, and New Drugs and Clinical Trials Rules, 2019: Relevant to regulated drugs, clinical investigations, and applicable stem-cell-derived products.

National Ethical Guidelines for Biomedical and Health Research Involving Human Participants: Relevant to ethical research, participant protection, and informed consent.

Consumer Protection Act, 2019: May apply to deficient medical services and misleading commercial claims, subject to the governing legal principles.

Professional medical standards: Practitioners must comply with applicable duties of competence, informed consent, and reasonable care.

The Supreme Court's decisions in Samira Kohli and Yash Charitable Trust are particularly useful when analysing consent and the difference between a claimed treatment and an intervention that meets accepted medical and regulatory standards.

(2008) 2 SCC 1+2

8. International legal considerations

International bioethics instruments provide useful guidance, although their legal force varies and they do not all create directly enforceable rights.

UNESCO Universal Declaration on Bioethics and Human Rights (2005): Addresses dignity, autonomy, informed consent, equality, non-discrimination, and social responsibility.

Convention on Human Rights and Biomedicine (Oviedo Convention, 1997): Establishes principles concerning consent, protection of persons undergoing research, and the human genome for its parties.

World Anti-Doping Code: Provides a separate framework for prohibited performance-enhancing substances and methods in sport.

These instruments demonstrate why enhancement questions cannot be resolved solely by asking whether a procedure is medically beneficial. The wider legal context may include human rights, research ethics, fairness, public health, and the prevention of exploitation.

9. A practical judicial decision-making framework

A court or regulator considering a disputed intervention could use the following sequence:

1

Identify the objective

Is the intervention intended to prevent or treat a medical condition, restore function, or improve an existing capability beyond a therapeutic objective?

2

Assess the evidence

Is the intervention supported by reliable evidence for the claimed purpose, and does it satisfy applicable approval and professional requirements?

3

Evaluate risk and alternatives

Consider severity of the condition, expected benefit, reversibility, long-term effects, and less risky alternatives.

4

Examine consent and equality

Determine whether consent is informed and voluntary and whether the intervention creates coercion, discrimination, or unjustified burdens on vulnerable groups.

5

Apply the relevant law

Determine whether the procedure is permitted, restricted to research, subject to licensing, or prohibited under the governing jurisdiction's specific rules.

This is a proposed analytical framework, not a claim that any one court has adopted these five steps as a binding universal test.

10. Conclusion

The legal threshold between therapy and enhancement is not simply the difference between an unhealthy and a healthy person. It involves the purpose of the intervention, the individual's circumstances, scientific evidence, the risks involved, consent, professional obligations, and the governing regulatory framework.

Three propositions are especially important:

Therapy is not automatically lawful: An intervention marketed as treatment may be impermissible if it lacks adequate evidence, regulatory compliance, or acceptable professional standards.

Enhancement is not automatically unlawful: Its legality depends on the procedure, its risks, the applicable laws, and the circumstances in which it is provided.

Autonomy is important but not unlimited: Consent supports bodily autonomy but does not override safety regulations, protect negligent practice, or create an automatic right to demand a particular procedure.

For Indian legal analysis, Samira Kohli v. Dr. Prabha Manchanda, K.S. Puttaswamy v. Union of India, and the 2026 Yash Charitable Trust v. Union of India proceedings offer particularly useful starting points. Together, they illuminate informed consent, constitutional autonomy, and the legal limits of describing an inadequately supported intervention as therapy.

The ultimate legal objective is to protect legitimate medical innovation and individual freedom while preventing unsafe experimentation, coercive enhancement, misleading commercial practices, and discrimination based on biological characteristics.